Cargando…
Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury
OBJECTIVE: Recent studies have suggested that high levels of β2-microglobulin are linked to cognitive deterioration; however, it is unclear how this connects to spinal cord injury (SCI). This study sought to determine whether there was any association between cognitive decline and serum β2-microglob...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183166/ https://www.ncbi.nlm.nih.gov/pubmed/37193029 http://dx.doi.org/10.7717/peerj.15372 |
_version_ | 1785041896176877568 |
---|---|
author | Cui, Zhonghao Wang, Shuai Hao, Yanke Chen, Yuanzhen |
author_facet | Cui, Zhonghao Wang, Shuai Hao, Yanke Chen, Yuanzhen |
author_sort | Cui, Zhonghao |
collection | PubMed |
description | OBJECTIVE: Recent studies have suggested that high levels of β2-microglobulin are linked to cognitive deterioration; however, it is unclear how this connects to spinal cord injury (SCI). This study sought to determine whether there was any association between cognitive decline and serum β2-microglobulin levels in patients with SCI. METHODS: A total of 96 patients with SCI and 56 healthy volunteers were enrolled as study participants. At the time of enrollment, specific baseline data including age, gender, triglycerides (TG), low-density lipoprotein (LDL), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), smoking, and alcohol use were recorded. Each participant was assessed by a qualified physician using the Montreal cognitive assessment (MoCA) scale. Serum β2-microglobulin levels were measured using an enzyme-linked immunosorbent assay (ELISA) reagent for β2-microglobulin. RESULTS: A total of 152 participants were enrolled, with 56 in the control group and 96 in the SCI group. There were no significant baseline data differences between the two groups (p > 0.05). The control group had a MoCA score of 27.4 ± 1.1 and the SCI group had a score of 24.3 ± 1.5, with the difference being significant (p < 0.05). The serum ELISA results revealed that the levels of β2-microglobulin in the SCI group were considerably higher (p < 0.05) than those in the control group (2.08 ± 0.17 g/mL compared to 1.57 ± 0.11 g/mL). The serum β2-microglobulin level was used to categorize the patients with SCI into four groups. As serum β2-microglobulin levels increased, the MoCA score reduced (p < 0.05). After adjustment of baseline data, further regression analysis showed that serum β2-microglobulin level remained an independent risk factor for post-SCI cognitive impairment. CONCLUSIONS: Patients with SCI had higher serum levels of β2-microglobulin, which may be a biomarker for cognitive decline following SCI. |
format | Online Article Text |
id | pubmed-10183166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101831662023-05-15 Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury Cui, Zhonghao Wang, Shuai Hao, Yanke Chen, Yuanzhen PeerJ Cognitive Disorders OBJECTIVE: Recent studies have suggested that high levels of β2-microglobulin are linked to cognitive deterioration; however, it is unclear how this connects to spinal cord injury (SCI). This study sought to determine whether there was any association between cognitive decline and serum β2-microglobulin levels in patients with SCI. METHODS: A total of 96 patients with SCI and 56 healthy volunteers were enrolled as study participants. At the time of enrollment, specific baseline data including age, gender, triglycerides (TG), low-density lipoprotein (LDL), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), smoking, and alcohol use were recorded. Each participant was assessed by a qualified physician using the Montreal cognitive assessment (MoCA) scale. Serum β2-microglobulin levels were measured using an enzyme-linked immunosorbent assay (ELISA) reagent for β2-microglobulin. RESULTS: A total of 152 participants were enrolled, with 56 in the control group and 96 in the SCI group. There were no significant baseline data differences between the two groups (p > 0.05). The control group had a MoCA score of 27.4 ± 1.1 and the SCI group had a score of 24.3 ± 1.5, with the difference being significant (p < 0.05). The serum ELISA results revealed that the levels of β2-microglobulin in the SCI group were considerably higher (p < 0.05) than those in the control group (2.08 ± 0.17 g/mL compared to 1.57 ± 0.11 g/mL). The serum β2-microglobulin level was used to categorize the patients with SCI into four groups. As serum β2-microglobulin levels increased, the MoCA score reduced (p < 0.05). After adjustment of baseline data, further regression analysis showed that serum β2-microglobulin level remained an independent risk factor for post-SCI cognitive impairment. CONCLUSIONS: Patients with SCI had higher serum levels of β2-microglobulin, which may be a biomarker for cognitive decline following SCI. PeerJ Inc. 2023-05-11 /pmc/articles/PMC10183166/ /pubmed/37193029 http://dx.doi.org/10.7717/peerj.15372 Text en © 2023 Cui et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Cognitive Disorders Cui, Zhonghao Wang, Shuai Hao, Yanke Chen, Yuanzhen Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury |
title | Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury |
title_full | Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury |
title_fullStr | Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury |
title_full_unstemmed | Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury |
title_short | Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury |
title_sort | higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury |
topic | Cognitive Disorders |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183166/ https://www.ncbi.nlm.nih.gov/pubmed/37193029 http://dx.doi.org/10.7717/peerj.15372 |
work_keys_str_mv | AT cuizhonghao higherserumb2microglobulinisapredictivebiomarkerforcognitiveimpairmentinspinalcordinjury AT wangshuai higherserumb2microglobulinisapredictivebiomarkerforcognitiveimpairmentinspinalcordinjury AT haoyanke higherserumb2microglobulinisapredictivebiomarkerforcognitiveimpairmentinspinalcordinjury AT chenyuanzhen higherserumb2microglobulinisapredictivebiomarkerforcognitiveimpairmentinspinalcordinjury |